Echo Therapeutics Sends Response to Shareholder Letter

            Echo Therapeutics Sends Response to Shareholder Letter

PR Newswire

PHILADELPHIA, Sept. 5, 2013

PHILADELPHIA, Sept. 5, 2013 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq:
ECTE), a medical device company developing its needle-free Symphony® CGM
System as a non-invasive, wireless, continuous glucose monitoring system,
announced that the independent members of the Board of Directors and Mr.
Robert F. Doman, the Executive Chairman and Interim Chief Executive Officer,
today sent a letter to its shareholder, Platinum-Montaur Life Sciences, LLC,
in response to an August 30, 2013 public communication made by
Platinum-Montaur and its affiliated funds. In addition, Echo has communicated
with Platinum-Montaur to discuss the matters raised in the August 30, 2013
communication. The Company and Platinum-Montaur have scheduled a meeting for
next week.

As Echo has previously announced, it continues to consider and seek to enter
into collaborations or licenses regarding the future development and
distribution of its products and remains willing to enter into discussions
regarding potential collaborations or licenses.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive,
wireless, continuous glucose monitoring system for use initially in the
critical care setting. Significant opportunity also exists for Symphony to be
used in the hospital beyond the critical care setting, as well as in patients
with diabetes in the outpatient setting. Echo is also developing its
needle-free skin preparation component of Symphony, the Prelude® SkinPrep
System, as a platform technology to enhance delivery of topical

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may
constitute forward-looking statements that are based on current expectations
and are subject to risks and uncertainties that could cause actual future
results to differ materially from those expressed or implied by such
statements. Those risks and uncertainties include, but are not limited to,
risks related to regulatory approvals and the success of Echo's ongoing
studies, including the safety and efficacy of Echo's Symphony CGM System, the
failure of future development and preliminary marketing efforts related to
Echo's Symphony CGM System, Echo's ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to Echo's and its
partners' ability to develop, market and sell the Symphony CGM System, the
availability of substantial additional equity or debt capital to support its
research, development and product commercialization activities, and the
success of its research, development, regulatory approval, marketing and
distribution plans and strategies, including those plans and strategies
related to its Symphony CGM System. These and other risks and uncertainties
are identified and described in more detail in Echo's filings with the
Securities and Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the year ended December 31, 2012, its Quarterly
Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no
obligation to publicly update or revise any forward-looking statements.

For More Information:

Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104

Connect With Us:

- Visit our website at
- Follow us on Twitter at
- Join us on Facebook at

SOURCE Echo Therapeutics, Inc.

Press spacebar to pause and continue. Press esc to stop.